p16(INK4a) expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma

Journal of Cutaneous Pathology

Volumn 25, Issue 6, 1998, Pages 291-296

  Funk, Jens Oliver ^a,c   Schiller, Peter I ^b   Barrett, Michael T ^a   Wong, David J ^a   Kind, Peter ^b   Sander, Christian A ^b  

^a USA   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; DNA; MICROSATELLITE DNA; PROTEIN P16INK4A;

ARTICLE; CONTROLLED STUDY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LENTIGO; MALIGNANT LENTIGO; MELANOMA; METASTASIS; METHYLATION; NEVUS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TUMOR CELL; CHROMOSOME 9; DNA METHYLATION; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; PATHOLOGY; PROMOTER REGION; SKIN TUMOR;

CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA; DNA METHYLATION; HUMANS; IMMUNOENZYME TECHNIQUES; LOSS OF HETEROZYGOSITY; MELANOMA; MICROSATELLITE REPEATS; PROMOTER REGIONS (GENETICS); SKIN NEOPLASMS;

EID: 0031594907     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0560.1998.tb01748.x     Document Type: Article

References (31)

1. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994: 266: 1821.
2. Barkova J, Lukas J, Guldberg P, et al. The p16-cyclin D/ Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996: 56: 5475.
3. Sherr CJ. Cancer cell cycles. Science 1996: 274: 1672.
4. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 1996: 8: 805.
5. Serrano M, Lee H-W, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996: 85: 27.
6. Kamb A. Cell-cycle regulators and cancer. Trends Gen 1995: 11: 136.
7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (London) 1993: 366: 704.
8. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994: 264: 436.
9. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (London) 1994: 368: 753.
10. Sherr CJ, Roberts JM. Inhibitors of mammalian GI cyclin-dependent kinases. Genes Dev 1995: 9: 1149.
11. Hayward NK. The current situation with regard to human melanoma and genetic interference. Curr Opin Oncol 1996: 8: 136.
12. Castellano M, Pollock PM, Walters MK, et al. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 1997: 57: 4868.
13. INK4b and genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 1996: 56: 5023.
14. +) anaplastic large cell lymphomas. Am J Pathol 1989: 135: 359.
15. INK4 expression in primary lung cancers and cell lines. Cancer Res 1995: 55: 505.
16. Foster SA, Wong DJ, Barrett MT, Galloway DA. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol 1998: in press.
17. Zhang L, Cui X, Schmitt K, Hubert R, Navidi W, Arnheim N. Whole genome amplification from a single cell: implications for genetic analysis. Proc Natl Acad Sci USA 1992: 89: 5847.
18. Barrett MT, Reid BJ, Joslyn G. Genotypic analysis of multiple loci in somatic cells by whole genome amplification. Nucleic Acids Res 1995: 23: 3488.
19. INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 1997: 57: 2619.
20. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996: 93: 9821.
21. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997: 11: 492.
22. Breslow A. Prognosis in cutaneous melanoma: tumor thickness as a guide to treatment. Pathol Annu 1980: 15: 1.
23. Merlo A, Herman JG, Mao L, et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1995: 1: 686.
24. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995: 55: 4525.
25. Reed JA, Loganzo F, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995: 55: 2713.
26. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T. Loss of expression of the p16/INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 1997: 74: 255.
27. Holland EA, Beaton SC, Edwards BG, Kefford RF, Mann GJ. Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma. Oncogene 1994: 9: 1361.
28. Healy E, Belgaid CE, Takata M, et al. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res 1996: 56: 589.
29. Gonzalgo ML, Bender CM, You EH, et al. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 1997: 57: 5336.
30. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995: 269: 1281.
31. INK4a binding domain of CDK4 in familial melanoma. Nature Genet 1996: 12: 97.